Edwards Lifesciences

Caption Health will use this funding to scale up its commercial operations, continue to develop its AI technology platform and form new partnerships. As more providers adopt the Caption AI platform, the company plans to add new clinical capabilities to expand the use of Caption AI in additional care settings.

Mitralign is a venture backed privately held company located in a suburb of Boston, MA. The company is developing an innovative catheter based technology for percutaneous treatment of functional mitral regurgitation. The novel Mitralign system emulates surgical annuloplasty as it delivers a series of surgical implants directly into the mitral annulus by means of a catheter. The implants are cinched together, thus reducing the size of the mitral valve annulus and the valve opening. Mitralign is funded by top tier venture capitalists and has two major cardiovascular device companies as investors.

Corvia Medical is a medical device company, focuses on developing structural heart devices for the treatment of heart failure. The company develops InterAtrial Shunt Device (IASD), a transcatheter device designed to treat diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). It was founded in 2009 and headquartered in Andover, Massachusetts.

CAS Medical Systems is dedicated to the design and manufacture of innovative, non-invasive technologies and products vital to patient care in the most challenging clinical environments. With a reputation for the highest quality products available in the markets it serves, CASMED products are used by clinicians worldwide.

V-Wave is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with Chronic Heart Failure (HF). V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave has developed a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity, and improve the overall quality of life. The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing, and bringing to market multiple implantable cardiovascular devices.

Harpoon Medical is a development stage medical device company commercializing a minimally invasive, image-guided surgical tool for beating heart mitral valve repair. The technology was developed in the Division of Cardiac Surgery at The University of Maryland School of Medicine. With the Harpoon device, surgeons can access and repair the mitral valve in a beating heart via a small incision between the ribs without the need for cardiac arrest or cardiopulmonary bypass. The tool enters the left ventricle transapically and inserts “bulky knot” neochords in the leaflet to eliminate mitral valve regurgitation. When introduced to the market, the Harpoon device should transform the traditional open-heart mitral valve surgical procedure from a complex 3-6 hour operation to a 60-minute procedure and reduce the recovery period from weeks to days.

Valtech Cardio (Israel) a development-stage medical device company focused on minimally invasive percutaneous annuloplasty ring valve repair for the treatment of mitral valve regurgitation.

Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.

V-Wave is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with Chronic Heart Failure (HF). V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave has developed a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity, and improve the overall quality of life. The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing, and bringing to market multiple implantable cardiovascular devices.

CardiAQ Valve Technologies (CVT), a privately held company, is developing innovative approaches to heart valve replacement and is initially focused on transcatheter mitral valve implantation (TMVI).

The Company, based in Menlo Park, has developed a novel transcatheter implant called the PARACHUTETM Ventricular Partitioning Device (PARACHUTETM). The PARACHUTETM intends to treat heart failure resulting from a heart attack or myocardial infarction in millions of patients worldwide by improving overall cardiac function.

Middle Peak Medical is a privately held medical device company focused on the development and commercialization of a novel technology to treat mitral valve disease. The company’s proprietary device has application in both percutaneous catheter-based intervention, and in minimally invasive or open-heart cardiac surgery.

BMEYE B.V., a non-invasive cardiovascular monitoring company, engages in the research and development of medical technologies for cardiovascular monitoring in the Netherlands and internationally. It offers finger arterial pressure and cardiac output technologies. The company's products include Finapres, a non-invasive continuous finger blood pressure monitor; Portapres, an ambulatory non-invasive continuous finger blood pressure monitor for measurements; Finometer, a stationary monitor with options for non-invasive brachial pressure and beat-to-beat hemodynamics; and BeatScope, a software package for the analysis of arterial pressure waveforms. Its products also comprise Modelflow, a model-based measurement method to compute the aortic flow waveform and cardiac outout from an arterial blood pressure waveform; Space instrumentation, a version of finger blood pressure monitors; Cardiopres, an ambulatory device for research on the interaction of electrophysiology, hemodynamics, and respiration; and Oxyflow, a hemodynamics and oxygen delivery monitor for experimental applications. In addition, the company offers Nexfin, a non invasive blood pressure and cardiac output monitor, as well as ccNexfin for applications in various areas, such as cardiology, anesthesiology, sleep observation, physiology, neurology, and internal medicine; and emergency, acute, intensive, and intermediate care. It offers its products through a network of distributors. BMEYE B.V. was founded in 2005 and is based in Amsterdam, the Netherlands.

Embrella Cardiovascular, Inc. develops a system to enhance embolic cerebral protection, enabling interventionalists to reduce the frequency of embolic strokes during cardiovascular procedures. Embrella Cardiovascular, Inc. is based in Malvern, Pennsylvania.

Embrella Cardiovascular, Inc. develops a system to enhance embolic cerebral protection, enabling interventionalists to reduce the frequency of embolic strokes during cardiovascular procedures. Embrella Cardiovascular, Inc. is based in Malvern, Pennsylvania.

myocor is a medical company that develops and distributes a range of therapeutic products to its clients. The company develops and provides evaluations on technologies to treat mitral regurgitation and heart failure. Furthermore, the technologies assist in the improvement of cardiac function. myocor was founded in 1996 and is based in Minnesota.

Whitland Research focused on the development of critical care monitoring technologies.

Vascular Architects, Inc. designs, develops, manufactures and markets devices used in the treatment of vascular stenoses, occlusions and non-vascular obstructions. A key area of emphasis is the treatment of peripheral vascular disease, which manifests itself as a reduction or loss of blood flow due to the narrowing or closing of arteries. Vascular Architects was founded in October 1997 by Thomas J. Fogarty, M.D. Dr Fogarty is an internationally renowned surgeon, professor, inventor and entrepreneur who has founded or cofounded more than 25 start-up companies that develop innovative medical devices. He has authored or coauthored over 150 professional articles, is a member of 29 professional societies, and is an inventor on more than 65 U.S. patents. Their founder and management team form a highly experienced group of technical, clinical and business personnel. Key opinion leaders in the interventional and vascular surgery communities have been recruited to serve on the Vascular Architects' Scientific Advisory Board.

As of January 27, 2004, Percutaneous Valve Technologies was acquired by Edwards Lifesciences Corp. The company develops medical devices for delivering heart valves to treat late-stage aortic stenosis. Percutaneous Valve Technologies, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.

Vascular Architects, Inc. designs, develops, manufactures and markets devices used in the treatment of vascular stenoses, occlusions and non-vascular obstructions. A key area of emphasis is the treatment of peripheral vascular disease, which manifests itself as a reduction or loss of blood flow due to the narrowing or closing of arteries. Vascular Architects was founded in October 1997 by Thomas J. Fogarty, M.D. Dr Fogarty is an internationally renowned surgeon, professor, inventor and entrepreneur who has founded or cofounded more than 25 start-up companies that develop innovative medical devices. He has authored or coauthored over 150 professional articles, is a member of 29 professional societies, and is an inventor on more than 65 U.S. patents. Their founder and management team form a highly experienced group of technical, clinical and business personnel. Key opinion leaders in the interventional and vascular surgery communities have been recruited to serve on the Vascular Architects' Scientific Advisory Board.

CardioFocus is a biotechnology company that focuses on the advancement of ablation treatments for cardiac disorders. The company specializes in providing electrophysiologists with innovative and effective tools that bring new levels of precision and control to the treatment of atrial fibrillation that focuses on developing, manufacturing, and investigating disposable fiber optic catheters for the visualization of cardiac anatomy and the treatment of cardiac arrhythmias. CardioFocus was founded in 1990 and is headquartered in Marlborough, Massachusetts.